GH Stock Summary and Trading Ideas (Guardant Health | NASDAQ:GH)

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health trades on the NASDAQ stock market under the symbol GH.

As of February 28, 2025, GH stock price climbed to $42.55 with 1,352,279 million shares trading.

GH has a market cap of $5.25 billion. This is considered a Mid Cap stock.

Last quarter Guardant Health reported $202 million in Revenue and -$.62 earnings per share. This beat revenue expectation by $9 million and missed earnings estimates by -$.12.

In the last 3 years, GH traded as high as $77.72 and as low as $15.81.

The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.

GH has outperformed the market in the last year with a return of +127.2%, while the SPY ETF gained +18.8%. In the last 3 month period, GH beat the market returning +21.2%, while SPY returned -0.4%. However, in the most recent 2 weeks GH has underperformed the stock market by returning -11.6%, while SPY returned -2.5%.

GH support price is $40.16 and resistance is $44.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.